Literature DB >> 14600027

Murine models of polycystic kidney disease: molecular and therapeutic insights.

Lisa M Guay-Woodford1.   

Abstract

Numerous murine (mouse and rat) models of polycystic kidney disease (PKD) have been described in which the mutant phenotype results from a spontaneous mutation or engineering via chemical mutagenesis, transgenic technologies, or gene-specific targeting in mouse orthologs of human PKD genes. These murine phenotypes closely resemble human PKD, with common abnormalities observed in tubular epithelia, the interstitial compartment, and the extracellular matrix of cystic kidneys. In both human and murine PKD, genetic background appears to modulate the renal cystic phenotype. In murine models, these putative modifying effects have been dissected into discrete factors called quantitative trait loci and genetically mapped. Several lines of experimental evidence support the hypothesis that PKD genes and their modifiers may define pathways involved in cystogenesis and PKD progression. Among the various pathway abnormalities described in murine PKD, recent provocative data indicate that structural and/or functional defects in the primary apical cilia of tubular epithelia may play a key role in PKD pathogenesis. This review describes the most widely studied murine models; highlights the data regarding specific gene defects and genetic modifiers; summarizes the data from these models that have advanced our understanding of PKD pathogenesis; and examines the effect of various therapeutic interventions in murine PKD.

Entities:  

Mesh:

Year:  2003        PMID: 14600027     DOI: 10.1152/ajprenal.00195.2003

Source DB:  PubMed          Journal:  Am J Physiol Renal Physiol        ISSN: 1522-1466


  75 in total

1.  Role of genetic modifiers in an orthologous rat model of ARPKD.

Authors:  Caitlin C O'Meara; Matthew Hoffman; William E Sweeney; Shirng-Wern Tsaih; Bing Xiao; Howard J Jacob; Ellis D Avner; Carol Moreno
Journal:  Physiol Genomics       Date:  2012-06-05       Impact factor: 3.107

2.  Rapamycin-mediated suppression of renal cyst expansion in del34 Pkd1-/- mutant mouse embryos: an investigation of the feasibility of renal cyst prevention in the foetus.

Authors:  Cherie Stayner; Justin Shields; Lynn Slobbe; Jonathan M Shillingford; Thomas Weimbs; Michael R Eccles
Journal:  Nephrology (Carlton)       Date:  2012-11       Impact factor: 2.506

3.  Loss of PKD1 and loss of Bcl-2 elicit polycystic kidney disease through distinct mechanisms.

Authors:  P Hughes; M Robati; W Lu; J Zhou; A Strasser; P Bouillet
Journal:  Cell Death Differ       Date:  2005-11-11       Impact factor: 15.828

4.  Loss of primary cilia upregulates renal hypertrophic signaling and promotes cystogenesis.

Authors:  P Darwin Bell; Wayne Fitzgibbon; Kelli Sas; Antine E Stenbit; May Amria; Amber Houston; Ryan Reichert; Sandra Gilley; Gene P Siegal; John Bissler; Mehmet Bilgen; Peter Cheng-te Chou; Lisa Guay-Woodford; Brad Yoder; Courtney J Haycraft; Brian Siroky
Journal:  J Am Soc Nephrol       Date:  2011-04-14       Impact factor: 10.121

5.  Glomerulocystic kidney disease in mice with a targeted inactivation of Wwtr1.

Authors:  Zakir Hossain; Safiah Mohamed Ali; Hui Ling Ko; Jianliang Xu; Chee Peng Ng; Ke Guo; Zeng Qi; Sathivel Ponniah; Wanjin Hong; Walter Hunziker
Journal:  Proc Natl Acad Sci U S A       Date:  2007-01-24       Impact factor: 11.205

6.  Genetic interaction studies link autosomal dominant and recessive polycystic kidney disease in a common pathway.

Authors:  Miguel A Garcia-Gonzalez; Luis F Menezes; Klaus B Piontek; Junya Kaimori; David L Huso; Terry Watnick; Luiz F Onuchic; Lisa M Guay-Woodford; Gregory G Germino
Journal:  Hum Mol Genet       Date:  2007-06-16       Impact factor: 6.150

7.  Inactivation of Pkd1 in principal cells causes a more severe cystic kidney disease than in intercalated cells.

Authors:  Kalani L Raphael; Kevin A Strait; Peter K Stricklett; R Lance Miller; Raoul D Nelson; Klaus B Piontek; Gregory G Germino; Donald E Kohan
Journal:  Kidney Int       Date:  2009-01-14       Impact factor: 10.612

8.  Src inhibition ameliorates polycystic kidney disease.

Authors:  William E Sweeney; Rodo O von Vigier; Philip Frost; Ellis D Avner
Journal:  J Am Soc Nephrol       Date:  2008-04-02       Impact factor: 10.121

9.  A mitotic transcriptional switch in polycystic kidney disease.

Authors:  Francisco Verdeguer; Stephanie Le Corre; Evelyne Fischer; Celine Callens; Serge Garbay; Antonia Doyen; Peter Igarashi; Fabiola Terzi; Marco Pontoglio
Journal:  Nat Med       Date:  2009-12-06       Impact factor: 53.440

Review 10.  Heterotrimeric G protein signaling in polycystic kidney disease.

Authors:  Taketsugu Hama; Frank Park
Journal:  Physiol Genomics       Date:  2016-05-13       Impact factor: 3.107

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.